Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease
Launched by UNIVERSITY OF CALIFORNIA, SAN DIEGO · Oct 10, 2018
Trial Information
Current as of May 02, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how a medication called memantine affects brain function and symptoms in people with Alzheimer's Disease. The goal is to find out more about which patients might respond best to this treatment. If you or a loved one has been diagnosed with Alzheimer's Disease and is between the ages of 50 and 83, you could be eligible to participate. To qualify, participants need to have a certain level of cognitive ability, confirmed by specific tests, and must have a caregiver who can provide support.
If you join the trial, you will be closely monitored to see how well memantine works for you. It’s important to note that not everyone will be able to participate; for instance, individuals with certain medical conditions or those currently taking specific medications may be excluded. This trial is currently recruiting participants, and it offers an opportunity to contribute to important research that could improve treatment for Alzheimer's Disease in the future.
Gender
ALL
Eligibility criteria
- Inclusion:
- • 1. Alzheimer's Disease Research Center-confirmed diagnosis of AD
- • 2. Mini-Mental State Examination (MMSE) score 10-22 OR a Montreal Cognitive Assessment (MOCA) score of 15-24
- • 3. Age 50-83 y
- • 4. Knowledgeable caregiver
- • 5. Ambulatory
- • 6. Medically stable;
- • 7. Audiometric testing (detection \< 40 db(A) at 1000 Hz)
- • 8. Informed consent
- Exclusion:
- • 1. Active systemic illness (e.g. heart disease, liver failure, renal insufficiency, cancer, HIV, tuberculosis, Hepatitis C)
- • 2. Current psychiatric or neurologic illness other than AD
- • 3. History of vascular disease, myocardial infarction, cerebrovascular accidents, transient ischemic attack, seizure, head injury with loss of consciousness; substance dependence (including alcohol and Opioid)
- • 4. Past treatment with memantine; unable to tolerate acetylcholinesterase inhibitor
- • 5. Investigational drug treatment \< 30 d of screening
- • 6. Current meds: amantadine, riluzole, other pro-cognitive medication, opioids
- • 7. Positive urine toxicology for non-prescribed psychoactive substance
- • 8. Actively enrolled in cognitive remediation therapy
About University Of California, San Diego
The University of California, San Diego (UCSD) is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a robust focus on translational medicine, UCSD leverages its interdisciplinary approach to explore groundbreaking therapies and interventions across a wide range of medical fields. The university's state-of-the-art facilities and collaboration with top-tier faculty and researchers ensure a comprehensive and ethical framework for conducting clinical trials, ultimately aiming to enhance patient outcomes and contribute to the global body of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
San Diego, California, United States
Patients applied
Trial Officials
Neal Swerdlow, M.D., Ph.D.
Principal Investigator
UCSD
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials